| Theme | Current Therapy of IBD | |
|---|---|---|
| Title | Optimization of Apheresis for Ulcerative Colitis and Crohn's Disease | |
| Publish Date | 2012/01 | |
| Author | Yoko Yokoyama | Division of Lower Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine |
| Author | Ken Fukunaga | Division of Lower Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine |
| Author | Takayuki Matsumoto | Division of Lower Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine |
| [ Summary ] | There have been recent advancements in therapies for inflammatory bowel disease (IBD). GMA was established as a treatment for refractory Crohn's disease (CD) patients in 2009. Intensive treatment with CAP was accepted for UC patients in 2010. We demonstrated that UC out-patients withmoderate activity are good candidates for weekly LCAP. A close correlation between UC duration and GMA response has been proven retrospectively. We have also used weekly GMA to treat refractory CD, especially biologic-refractory conditions. CAP is the original Japanese adjunct therapy for refractory IBD. To provide optimal care we must prescribe the best means to reinforce clinical efficiency for eachform of CAP. | |